FluGen announced today it has dosed its first patients in a clinical trial of a novel investigational influenza vaccine called M2SR against multi-season mismatched strains, in Belgium. “If successful, the results from…
Cellectar Biosciences announced today that the U.S. Food and Drug Administration has granted rare pediatric disease designation (RPDD) to its phospholipid drug conjugate, CLR 131, for the treatment of neuroblastoma….
Propeller Health’s respiratory management system was used to reduce asthma burden in a recent study published in the healthcare journal Health Affairs, the company announced recently. According to a release,…
The U.S. Patent and Trademark Office has awarded Cellectar Biosciences a patent (No. P150207US03) that covers a method of use for CLR 131 in multiple myeloma, the company announced today….
Exact Sciences named Mark Stenhouse as president of Cologuard, its noninvasive stool DNA-based test for early detection of colon cancer, the company announced recently. “More than 85 million people are…
Cellectar Biosciences has been granted orphan drug designation for its therapeutic, CLR 131, by the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development for the treatment of neuroblastoma,…
Exact Sciences named Paul J. Limburg, M.D., M.P.H., as its co-chief medical officer, the company announced today. “Dr. Limburg’s valuable mix of cancer prevention experience in both the clinical and…
Exact Sciences’ Cologuard has been used in more than one million screenings for colorectal cancer, the company announced today. “Approximately half of Cologuard users haven’t been screened before, and we’re…
Lucigen announced today that it has been acquired by LGC, an international, privately owned company in the extended life sciences sector that seeks to strengthen its reagents offering in the genomics…
SHINE Medical Technologies has completed construction and taken occupancy of Building One, the first building of its medical isotope production campus, the company announced today. “Building One’s name was chosen…
